Stock Picks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gerald just now on twitter "@G_Commish: Amarantus will only effect a reverse split in conjunction with a pre-approved up-listing to a national exchange. Period."
"We will issue a PR announcing DTC eligibility as soon as we have the effective date." This makes me think Ed's got multiple PRs ready to go!!! $MYEC
Takeoff! $AMBS
New Video from CEO Live!!!
http://ceolive.tv/marani-brands/mrib-videos/2182-ceolive-tv-interview-marani-brands-mrib
Ed on Facebook, "we are on schedule for rolling out service with our app."
Obvious website glitch. It jumped from 3 days to 50 days to 20 days. 20 days from now is a Saturday. Hope they fix it by tomorrow. $MYEC
Indianapolis, Indiana in the house. Lets break through .04 today. Ed's got a bunch of PRs he is holding and waiting To drop next week as soon as the DTC eligibility Happens. $MYEC
MJ-Pay is all the talk but $MYEC is about to take over the Government and Health care industries. The two new additions to Senior Management specialize in these fields. William J. "Bill" Delgado specializes in digital technology solutions for the government. Rod Jalunardo specializes in digital health information & medical data. KABOOM!
"Very exciting times now and ahead, we are already a much different company that we were just 2 months ago." - Ed Starrs
BATTER UP! Ed is calling his shot! MJ-Pay.com could come early! Looking like a Homerun! -Ed Starrs $MYEC
Almost feel like this was Ed's gift to all the longs. He goes silent for 3 weeks knowing all the longs can load up cheap shares. Then he can explode the PPS. What a nice guy! $MYEC
Added 100,000 shares at .032. I'm ready for this to explode in May. $MYEC
Today new hire William J. "Bill" Delgado, MBA, has 33 years of technology management experience as CEO, CFO and Director, recently instrumental in the success of GDSI, Inc., a digital technology solutions provider to governments. They are going hardcore at all government processing. $MYEC
Well I had emailed them to give us some details about the Mexico deal and it looks like they listened. I'm excited about the new Money TV. Now we need more details about Brazil and Dominican Republic also.$MRIB
$MYEC won the California government contract to process payment data for CalSTRS. (Which I believe is all the teacher pension funds)
http://finance.yahoo.com/news/myecheck-launches-application-government-government-164500456.html
This company needs some PR help. Why are these PRs so vague? We sold some vodka to Mexico. Who is the contract with? To a distributor in Mexico? To the mexican government? To a drug kingpin?
A few years ago, I might have panicked. But I know what I own and holding strong. $MYEC will have over 10 million in revenues in 2014. 20 million in 2015. So it just makes sense to hold on to this one for retirement.
Commercialization On-Track for 2014: Updating LymPro Test® Progress
The Company remains on track to commercialize the LymPro Test® in the second half of 2014. Since the fourth quarter, when we last updated our shareholders on the progress of LymPro, we have achieved a number of key milestones that we believe will add significant value to our product as well as mitigate risk in certain critical areas in order to increase the net present value of our assay. As a result of these steps, we are in a position to initiate a partnering process for the CLIA commercial launch of LymPro in the second half of 2014. The Company has made progress in the following areas:
Confirming findings from previous studies;
Improving the commercial viability of the assay and maximizing the timeframe of our proprietary position as the sole marketer for LymPro Test®;
Completing certain essential validation steps required to analytically validate LymPro;
Retaining stellar talent to lead our product development and scientific marketing efforts;
Establishing a reimbursement framework to support the commercial launch of LymPro.
As a result of improvements in these critical areas, the Company initiated a partnering process in the first quarter of 2014 for the CLIA commercial launch of LymPro, and thereafter will evaluate the ex-US commercialization strategy.
With the recent publicity in the mainstream media regarding competitive academic-stage diagnostic blood tests for Alzheimer’s disease, it is clear that there is considerable interest from the public at large in our specific subsector of Alzheimer’s diagnostics. We believe this interest is due to the massive unmet medical need that a blood-based diagnostic test would fill. As we prepare for LymPro’s commercialization in the second half of 2014, we believe it is critical to properly position LymPro within the scientific community, the investment community and the general population as THE commercially-validated blood test as we prepare for product launch. We want to ensure LymPro will not be overlooked by the scientific community when our next set of results are released.
As a result of this, our next key area of importance will be to ensure that when the pilot data is publicly released by the Company, it will have been generated in our commercially validated assay. Among the primary differences between LymPro Test® and our academic competition is that LymPro is well ahead in terms of commercial development. It is essential going forward that the Company release results produced solely from the validated assay in order to maintain commercial credibility for our claim set. The Company remains on track to complete CLIA-grade validation and preparation of the Analytical Performance Package (APP) for LymPro in the first half of 2014. We have begun the implementation of our commercial scientific marketing strategy and that foundation begins with an analytically validated assay. We believe this rigor going forward will lead to the most successful commercial launch in the second half of this year and allow us to achieve our corporate objective of establishing LymPro as the standard Alzheimer’s Blood Test in the industry by nurturing the market through its infancy as we prepare LymPro for FDA submissions.
To this end, we have recently hired Paul Jorgensen, our new Head of Product Development, to ensure the validation process is executed to the utmost commercial standards. Mr. Jorgensen most recently was responsible for successfully commercializing a pre-diabetes blood test under CLIA at Tethys Bioscience. We believe there are many parallels to establishing a blood test for Alzheimer’s as in diabetes, especially where there is a period of diagnostic uncertainty while the underlying disease mechanism progresses to a clinical diagnosis. Diabetes is a major international health problem with long-term health consequences, and Dr. Jorgensen’s regulatory experience with regards to these matters will be highly valuable here at Amarantus.
From the Alzheimer’s clinical development standpoint, this morning the Company announced the appointment of Dr. Louis Kirby to our Board of Advisors. Dr. Kirby brings with him deep industry perspective as a Board Certified neurologist who has served as principle investigator on nearly 400 clinical trials. Combined with the insights provided by Dr. Adam Simon and Dr. Colin Bier, Dr. Kirby’s experience will greatly advance the Company’s thinking in terms of our clinical development program in light of recent decisions at the FDA regarding accepted standards for Alzheimer’s biomarker approval.
On March 20th, 2014, the FDA approved an amyloid imaging agent being developed by Piramal Imaging’s Neuraceq®, the third such approval at the FDA on the heels of approvals for Avid Radiopharmaceuticals and GE. We believe this approval represents a shift in the agency’s thinking regarding biomarkers for Alzheimer’s disease, and is a statement regarding the importance of new products in the quickly evolving ‘gold standard’ in-life diagnostic paradigm for Alzheimer’s disease. As a result, we will be working closely with Dr. Kirby and our other advisors to prepare updated clinical development protocols and provide the most compelling data to our early customers for LymPro: pharmaceutical companies and Key Opinion Leading physicians. We are currently seeking counsel with our regulatory consultants regarding the appropriate FDA strategy, and expect to initiate a dialogue with the agency upon completion of the APP for LymPro. We are hopeful this dialogue will ultimately facilitate FDA approval for LymPro and catalyze market penetration. In total, 900 total patient samples were required for FDA approval of Neuraceq between disease and control arms, and we believe this may serve as a roadmap for ultimate regulatory approval for LymPro.
As a result of the experience gleaned from Avid’s attempts to gain reimbursement for Amyvid, the first PET imaging agent approved by the FDA for Alzheimer’s disease, we believe it will not only be critical to show efficacy of LymPro, but for widespread market penetration it is important to demonstrate a straightforward reimbursement pathway for our product. We have retained Boston Healthcare to assist us with our reimbursement strategy and believe we have developed a strong framework that will form the basis of a successful and sustainable reimbursement profile for LymPro.
In summary, we have continued to make progress in recent months with our LymPro product development program and have put ourselves in a position to develop a meaningful commercialization and marketing partnership for our CLIA assay as we head into the second quarter of 2014. We will continue to update our shareholders of critical milestones as they are achieved, with the next milestones expected in the second quarter as we prepare the marketing process for LymPro’s commercialization in the US. This effort will begin with the investment community at the Cavendish Global Health Impact Forum at the United Nations in New York in early May and will continue with the scientific community at the Alzheimer’s Association’s International Conference (AAIC) in Copenhagen in mid-July. We believe these two conferences will set the stage for successful marketing efforts upon commercialization in the second half of the year.
I look forward to updating you in the weeks ahead regarding LymPro and the Company’s other development programs, including MANF and Eltoprazine. The Company will also continue to bolster our executive team in preparation for up-listing the Company’s common stock to a national exchange in 2014, as well as evaluate various strategies to improve the value of the Company’s common shares for our loyal shareholder base. The Company’s recent financing transactions position the Company to be well capitalized to achieve our objectives and thrive in the years ahead. We expect to strategically utilize our capital to build long term shareholder value, while also further reducing our enterprise risk by leveraging the deep scientific, product development and business talent of our management team, Board of Directors and Board of Advisors.
Thank you for taking the time to read this blog, I welcome feedback and will continue to strive to address key Company and industry issues. I encourage shareholders to follow and engage with the Company through our social communication channels. We believe Amarantus’ best days are certainly in front of it and look forward to sharing this progress with you.
Warmest Regards,
Gerald E. Commissiong
President & CEO
Amarantus Bioscience Holdings, Inc.
http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/commercialization-track-2014-updating-lympro-test-progress/
We are moving up!!! Does someone know something?
How in the hell do we announce a distribution deal with over 75 different businesses including Costco and go red??? $MRIB
New Article!
Myecheck Inc : Changing Face Of Electronic Payments
MyEcheck Inc. (OTCMKTS:MYEC) has been a long-time player in the electronic payment segment for some time now. Leveraging its sustainable technology expertise in fully-integrated electronic payment solutions, the company has since released a new product called as G-Pay.
What is MyECheck G-Pay?
MyEcheck Inc (OTCMKTS:MYEC) has moved a step ahead of swipe card and even smart card payment structures to fully-fledged electronic real-time transactions with its ambitious payment platform.
This time, the payment solutions finder has reshaped the future of government payment with its unique G-Pay solution.
The solution is to be sold through internal inventories to various government bodies to allow complete end-to-end electronic payment process. These will be sold to resellers and contracted payment service providers.
G-pay is in real terms a plug-in for its MyECheck version 3.0 and has addressed security risks for government departments within the electronic payment segment.
The key feature on G-Pay is to allow fund transfer of authorized fund from any government checking account.
California appointed vendor
MyEcheckInc (OTCMKTS:MYEC) has also announced that it has appointed the State of California as the qualified vendor and can seek contracts from the government to render payment services.
The company also announced that it has also empanelled itself to be eligible for government contracts through the BidSync system.
MyECheck has already participated in such bids successfully and has also been successful as a contractor to process data of payments applicable to CalSTRS.
With the electronic form, the company has successfully built the ideal platform for government to bring in electronic transaction with the current systems of check payment and issuance remaining in place. The company has also stated that the government will be able to take advantage of the tax payment as well as Business and personal payment structures through G-Pay.
http://www.livetradingnews.com/myecheck-inc-otcmktsmyec-changing-face-of-electronic-payments-38972.htm
$MYEC
Costco is on their distributor list in California! This is huge. I like that! $MRIB
Dr. Victor's company ReGen Medical is hosting the big Stem Cell conference tomorrow! I'm sure he will be accumulating more partnerships for clinics. Having James Andrews by your side will be a huge help. Possibly big news tomorrow??? $SVFC
http://arminvestorday.com/
Twitter: @Maranivodka: Exciting News - Hi Time Wine Cellars starts shipping Marani Spirit across US TODAY, To order your bottle, go to http://t.co/CG2cm1aKU2
Doctor Vic is making moves! He is building value for long term growth and expansion. Big explosion in PPS is coming. $SVFC
So what does this SEC filling mean? Some dude bought 41 million shares and has voting power?
Big news coming! 8 State Distribution. Possible National Safeway contract! Mexico contract? Europe Contract? South Africa Contract? Don't get left out! $MRIB
Kirk, Boxer Introduce Bill To Support Regenerative Medicine Research
WASHINGTON – U.S. Senators Mark Kirk (R-Ill.) and Barbara Boxer (D-Calif.) today introduced legislation to help accelerate the discovery of new cures for traumatic injuries and diseases including Alzheimer's, cancer, diabetes, and ALS (commonly known as Lou Gehrig's disease) by establishing a national strategy to support research into regenerative medicine. Regenerative medicine has the potential to treat and even cure many serious medical conditions through the regeneration of human cells, tissues, or organs to replace those that are damaged or failing.
"As a stroke survivor, I know firsthand the importance of medical research and therapy," Senator Kirk said. "Regenerative medicine would benefit the lives of countless Americans, including those suffering from chronic and life-threatening diseases or injuries, and builds on our success in stem cell research."
"Regenerative medicine gives priceless hope to millions of Americans who are suffering from life-threatening or debilitating conditions," Senator Boxer said. "This bill will help make the promise of these medical breakthroughs a reality for this generation and generations to come."
While regenerative medicine is already in use to treat wounds, cartilage defects, and diabetic foot ulcers, these successes are potentially just the beginning. Regenerative medicine holds the promise of treating many costly diseases and injuries, such as those sustained by soldiers in battle, while reducing health spending and promoting economic growth. However, more research into the basic science of regenerative medicine is needed. A Department of Health and Human Services (HHS) report recommended that the United States develop a national regenerative medicine strategy in order to take full advantage of regenerative medicine's potential and advance the development of these innovative treatments and cures.
To achieve these objectives, the Regenerative Medicine Promotion Act would require the Government Accountability Office to issue a report identifying all ongoing federal programs and activities regarding regenerative medicine. The bill would also require the Secretary of HHS to establish a Regenerative Medicine Coordinating Council comprised of Cabinet secretaries, agency heads, researchers, experts, and advocates to develop and maintain a national strategy for the promotion of regenerative medicine research and development. The Council would be tasked with identifying priorities and sources of funding for research into regenerative medicine and recommending policies to overcome barriers in research and product development.
One study estimated that regenerative medicine could save the U.S. $250 billion per year in direct costs associated with late-stage Parkinson's disease, new cases of spinal cord injury, heart failure, stroke, and insulin-dependent diabetes.
The Regenerative Medicine Promotion Act has the support of the Alliance for Regenerative Medicine, a coalition of 80 advocacy groups, research institutions, and stakeholders including the ALS Association, the Juvenile Diabetes Research Foundation, the National Stem Cell Foundation, the National Multiple Sclerosis Society, and the Parkinson's Action Network.
http://www.kirk.senate.gov/?p=press_release&id=1025
Yes! Great news. Stem Cell sector will begin a massive breakout in 2014! And guess who has the patents! Buy and hold. $SVFC
SVFC Slideshow Highlights:
http://proactivecapital.com/wp-content/uploads/2013/02/intellicellInvestorPP.pdf
-New Flagship Facility on Park Ave, NY, with projected revenue $10-12 million
-Starts slowly at 2 facilities added per year, ramps to over 10 per year
-By 5th year 40 remote facilities bring Total Revenue over $220M
Performance Details
-Each New Facility incurs a one-time $800k acquisition and startup cost
-Each New Facility yields $6.4M annual revenue with $3.2M annual profit
-Total 5th year expenses of $117M yield Gross Profit of $106M
-Profitable all 5 years with increasing Gross Margin from 18% to 47%
IntelliCell Partners:
-Andrews Orthopedic Center
-Rutgers
-NYU Langone Medical Center
-Winthrop University Hospital
-UCL
-Biologics
-EMD Millipore (a Division of Merck)
-Buchanan Ingersoll
-University of Florida
-Sichenzia Ross Friedman Ference
-Numoda
$SVFC
Loading Zone today! This will slowly creep up over .01 in the next week. Then over .05 with anymore clinics or International Patent approval. $SVFC
SVFC will receive $2500 per Treatment from AREF! This is a non-exclusive contract. So basically SVFC can have License Agreements all over the world as soon as International Patents are granted! How many will they have in a few years? All over US, Korea, Thailand, Canada, etc.
This has potential to take off like a rocket.
http://biz.yahoo.com/e/140312/svfc8-k.html
$SVFC
SVFC agrees to license technology to The Andrews Research and Education Foundation, Inc.!!!
($2,500.00) per Tissue Processing! $$$
Big Money coming!!!
http://biz.yahoo.com/e/140312/svfc8-k.html
$SVFC
Wow! Great News!
400,000,000 shares of the Company’s common stock at an exercise price of $0.005 per share. I'm loving this finance deal. Now they need to PR the news about a clinic rollout and pps will shoot to .05-.10
$SVFC
$$$ Looks like big partnership to roll out clinics! Financing is in place. Now we just need a PR about partner and how many clinics!!! Exhibit 10.4
Guaranty Agreement, dated March 11, 2014, by and among the Company, Intellicell NY, ICBS, Tech-Stem, and the Investor.
Final court date is scheduled for 3/19/14.
INTELLICELL BIOSCIENCES has already won the case.
Index Number: 652800/2013
Case Name: INTELLICELL BIOSCIENCES INC. vs. IRONRIDGE GLOBAL IV, LTD.
https://iapps.courts.state.ny.us/webcivil/FCASSearch?txtIndex=652800/2013&cboCounty=30&from=Y
Will we see a PR before then? Or will they wait until the case is over?
$SVFC
Great opportunity to buy cheap shares right now before HUGE PR hits! Expecting PR before Friday. My guess is a partnership to roll out clinics. Anyone want to try and call Anna and see if she will give us a timeframe? $SVFC
CNN: Blood test predicts Alzheimer's disease
http://www.cnn.com/2014/03/09/health/alzheimers-blood-test/
(CNN) -- In a first-of-its-kind study, researchers have developed a blood test for Alzheimer's disease that predicts with astonishing accuracy whether a healthy person will develop the disease.
Though much work still needs to be done, it is hoped the test will someday be available in doctors' offices, since the only methods for predicting Alzheimer's right now, such as PET scans and spinal taps, are expensive, impractical, often unreliable and sometimes risky.
Alzheimer's & Sleep Study: Vitamin E slowed Alzheimer's Seth Rogen slams senators
"This is a potential game-changer," said Dr. Howard Federoff, senior author of the report and a neurologist at Georgetown University Medical Center. "My level of enthusiasm is very high."
The study was published in Nature Medicine.
'We were surprised'
In the beginning, the researchers knew they wanted to find a blood test to detect Alzheimer's but didn't know what specifically to look for. Should they examine patients' DNA? Their RNA? Or should they look for the byproducts of DNA and RNA, such as fats and proteins?
They decided to start with fats, since it was the easiest and least expensive. They drew blood from hundreds of healthy people over age 70 living near Rochester, New York, and Irvine, California. Five years later, 28 of the seniors had developed Alzheimer's disease or the mild cognitive problems that usually precede it.
Scouring more than 100 fats, or lipids, for what might set this group apart, they found that these 28 seniors had low levels of 10 particular lipids, compared with healthy seniors.
To confirm their findings, the researchers then looked at the blood of 54 other patients who had Alzheimer's or mild cognitive impairment. This group also had low levels of the lipids.
Overall, the blood test predicted who would get Alzheimer's or mild cognitive impairment with over 90% accuracy.
"We were surprised," said Mark Mapstone, a neuropsychologist at the University of Rochester Medical Center and lead author of the study. "But it turns out that it appears we were looking in the right place."
Alzheimer's risk before symptoms: Do you want to know?
The 'holy grail'
The beauty of this test, Mapstone says, is that it caught Alzheimer's before the patient even had symptoms, suggesting that the disease process begins long before people's memories start failing. He says that perhaps the lipid levels started decreasing at the same time as brain cells started dying.
He and his team plan to try out this test in people in their 40s and 50s. If that works, he says, that would be the "holy grail," because then researchers could try experimental drugs and treatments in a group that's almost sure to get the disease. That would speed research along immensely.
Plus, people could get a heads up that they were probably destined to get Alzheimer's. Although some people might not want to know that they're destined for a horrible disease, others might be grateful for the warning.
Federoff said he would want to know whether he was on his way to getting the disease, even though there's nothing he could do about it. He might want to take a family trip he'd been thinking about or might want to appoint a successor at work.
"I would make sure that things that are important to me get done," he said.
But, Federoff added, others might not want to know they were about to get a devastating disease they were powerless to stop.
"I think it's a very personal decision," Federoff said. "It would have to be thought through on multiple dimensions. Patients and their families would have to be counseled."
Next steps
Other research teams are looking at other possible tests for Alzheimer's. The need for a screening test of some kind for Alzheimer's has never been greater: A report released last week says the disease claims the lives of perhaps a half a million Americans, making it nearly as deadly as heart disease and cancer.
If any of these tests work out -- and that's still an if -- it would take years to make it to doctors' offices, since the test would need to be validated by other labs and with larger groups of people. Thee test developed by the Georgetown and Rochester researchers, for example, was used mainly in white people, and it might not work as well with other groups.
Heather Snyder, a spokeswoman for the Alzheimer's Association, said the study was well done but much work is still needed.
"It's an interesting paper. It's an intriguing study. But it is very preliminary," she said.
$AMBS
MyECheck’s Mobile Product Strategy:
http://www.myecheck.com/2014/03/07/myechecks-mobile-product-strategy/
MyECheck’s strong competitive advantage as an electronic payment platform is its exclusive ability to enable transfers from any checking account. And the transactions are faster, safer and lower cost than ACH and card transactions. The benefits are substantial making the MyECheck platform clearly superior in many ways for mobile payments.
MyECheck provides three types of mobile payment solutions for different applications:
1) As a backend or wholesale processor to Mobile Payment Service Providers (MPSP)s. These include payment processors, e-wallets, stored value, and large merchant proprietary payment systems. The MPSP integrates with MyECheck in the tradition manner.
2) As a MPSP with a comprehensive solution for POS purchases on mobile devices.
3) As a licensor of customized mobile payment solutions.
MyECheck will be launching new products in the coming weeks and months including an end-to-end turn-key mobile payments solution that any business can easily implement remotely. The retail Point Of Sale system will include user apps for Apple and Android devices, and a download merchant POS app that runs on Quickbooks accounting software.
There are two mobile payment systems, one has higher security and has been developed for regulated industries. The other has been developed for retail sales, however the set-up and process flow is almost identical.
The Merchant only requires an internet connected computer with Quickbooks and a bank account, the User only requires an internet connected mobile device or tablet and a checking account.
The process flow for remote registration apps the regulated industries system:
Merchant downloads, installs and registers MyECheck Merchant App
User downloads and installs MyECheck User App
User selects Merchant in User App Merchant Menu
User enters Registration Data and submits to Merchant App
Merchant App validates Bank Data and Pre-Approves/Declines User Account
User presents ID at Merchant Location, Merchant compares to Registration Data
Merchant App displays QR code to User App containing User Account Token
At POS Merchant App displays QR code to User App containing Invoice
User App displays Transaction Detail and prompts authorization
User authorizes payment by sending Token to Merchant App
Merchant App verifies User Bank Account and Approves/Declines Transaction
Merchant App sends receipt to User App
MyECheck backs up transaction data at an independent data warehouse.
With this uniquely broad range of capabilities, MyECheck can serve almost any customer in any market either directly or through one of MyECheck’s licensees or MPSP partners. This model also enables growth through leveraging partners’ existing customer base and sales and marketing resources.
$MYEC